Book a Meeting

Communication Strategy for Early-Stage Biotech Companies

Innovare Bioadvisors is a boutique life sciences strategic advisory firm dedicated to partnering with therapeutic innovators to effectively influence diverse stakeholders including investor, science, medical and corporate communication audiences.

Learn more


This is where the value of your science grows and evolves as markets accelerate.

Our team excels at engaging key stakeholders – including Key Opinion Leaders (KOLs), healthcare providers, investors, business development teams, and the general population – to deliver tailored strategies that amplify scientific innovation and drive meaningful connections.

WHO ARE WE?

Founder Led, Founder Partnership

Richard Veal, MBA

Founder, Managing Partner

Communications Strategy

Background:

  • 20+ years of biopharma pre-commercial, go-to-market, and launch activation expertise
  • management consulting, KOL market research, omni-channel planning, communication strategy.

Expertise:

  • Emering Biopharma Asset Strategy & Comms. Planning
  • Pipeline Planning & 3-5 Year Road Maps
  • KOL/HCP/Stakeholder Market Research

Jeff Martin, PhD

Co-Founder, Partner

Scientific & Medical Strategy

Background:

  • PhD training and research across cancer genetics, genomics, immunology, and cell therapy.
  • Post-doc research at NCI Roswell Park Comprehensive Cancer Center, NY state’s only NCI-designated cancer center outside of NYC.

Expertise:

  • Scientific and Medical strategy for Emerging Biopharma
  • Competitive Intelligence and Science Communications
  • Capability to Lead and Translate Complex Science Into Approachable Multi-stakeholder Communication Programs

We also have a robust support team across science, medical, creative, communications, and editorial disciplines.

We are specialists in first-in-class therapeutics

Here is just a handful of the groundbreaking technologies our team has worked on.

FIRST GENE THERAPY to receive FDA approval for potential cure in beta thalassemia

(ß-Thalassemia, ZYNTEGLO, Bluebird Bio)

FIRST TARGETED RADIOLIGAND THERAPY FDA approved for prostate cancer

(PSMA+ Prostate Cancer, PLUVICTO, AAA/NVS)

FIRST LENTIVIRAL VECTOR GENE THERAPY to receive FDA approval for sickle cell disease

(Sickle Cell Disease, LYFGENIA, Bluebird Bio)

FIRST LECTIN PATHWAY-SPECIFIC COMPLEMENT INHIBITOR for clinical use

(Stem Cell Transplant TMA, Narsoplimab, OMEROS)

First BISPECIFIC T CELL ENGAER to receive FDA approval for solid tumors

(Uveal Melanoma, KIMMTRAK, Immunocore)

FIRST BCMA-TARGETED ANTIBODY-DRUG CONJUGATE

(R/R Multiple Myeloma, BLENREP, GSK)

WHAT CAN WE DO FOR YOU?

Core Offerings/Key Deliverables

Lexicon platform (by stakeholder group)/Science position and messaging development

Scientific communication platform (SCP) workshop and internal team consensus building

Mechanistic lexicon audit & white space analysis

Science influencer strategy

Target product profile (TPP) development

Corporate communications strategy

Stakeholder market research

Ongoing competitive intelligence

Book a consultation

Ready to take your biotech venture to the next level? Schedule a consultation today and discover how Innovare can support your journey.

[email protected]